This piece explains healthcare investing's unique logic: drugs have long, costly development phases, then a profitable period, followed by a sharp revenue drop from patent expirations. RTW fund sees a 'golden age of drug discovery' driven by new modalities like gene therapy and RNA, with the US dominating. Key holdings: Avexis (early investment, later bought by Novartis for ~$9B), Novo Nordisk (up ~7x in a decade), and Eli Lilly (up ~10x). They warn the US Inflation Reduction Act shortens drug revenue periods, potentially stifling innovation.
RTW Investments founder and CIO Rod Wong, along with Chief Commercial Officer Stephanie Sirota, delve into the uniqueness of healthcare investing. Their core thesis is: The product lifecycle of healthcare products (no-revenue period → strong revenue period → patent cliff) dictates the industry structure, making the U.S. the dominant force in global biotech. The current era is a "Golden Age of Drug Discovery" driven by new modalities (gene therapy, RNA, cell therapy, etc.).
Rod Wong argues that the product lifecycle of healthcare (especially drugs) is fundamentally different from other industries, comprising three distinct phases. The first phase is a revenue-free period lasting over a decade, accompanied by extreme capital intensity ("it takes over a billion dollars to get a drug across the finish line"). The second phase is a revenue period characterized by non-cyclicality, relative pricing power, and predictability. The third phase involves revenue "falling off a cliff very rapidly," forcing companies to constantly reinvent themselves. This lifecycle creates a polarized industry structure: a vast number of micro-cap biotech companies reliant on the deep U.S. public capital markets ("venture capital in the public markets") on one end, and a few large multinational pharmaceutical companies on the other, which struggle to sustain long-term growth due to their own product cycles.
Rod Wong uses the investment in Avexis as an example of identifying disruptive opportunities from early, non-traditional data. They invested based solely on preclinical (animal) data, observing a key experiment: pigs with spinal muscular atrophy (SMA) "fully recovered and were running around" after receiving gene therapy. This was a "huge aha moment," leading them to believe that gene therapy as a new modality could succeed and that SMA could be one of the first diseases conquered. Despite a rocky path ahead, Avexis was eventually acquired by Novartis for nearly $9 billion. Rod notes that while this case had highly compelling early data, most drug development is not like this; the key is identifying which experimental results are "predictive of future success" ("some types of experiments translate nine times out of ten, and others translate one percent of the time").
Rod Wong and Stephanie Sirota believe the industry is entering an innovation explosion driven by multiple new modalities. Over the past 5-10 years, new modalities like gene therapy, RNA, cell therapy, protein degraders, bispecific antibodies, antibody-drug conjugates, and radiopharmaceuticals have emerged en masse. Last year, the U.S. set a record with 61 new drug approvals, nearly a quarter of which came from these new modalities. They predict that in 5-10 years, annual approvals could reach 80-100, with new modalities accounting for half. To capture this opportunity, RTW has proactively evolved from a small early-stage team into a "modern assembly line" of about 75 employees, including experts across different therapeutic areas and functions, becoming a public and private market investor. Stephanie emphasizes that this team-based, deeply specialized structure is key to navigating the innovation explosion and represents a major challenge within the industry.
Rod Wong points out that while exciting innovation exists in Europe and China, the depth of the U.S. capital market gives it absolute dominance in biotech. Regarding China, he believes the biggest opportunity is not investing in its listed companies, but rather "forming partnerships with Chinese companies to bring assets into Western or global enterprises," as these enterprises can provide capital that Chinese companies struggle to access. This reflects a structural mismatch between global innovation distribution and capital accessibility.
Rod Wong argues that the IRA, by shortening the revenue period for drugs, is distorting investment decisions and potentially suppressing innovation. The act disproportionately impacts small molecule drugs for age-related diseases, shortening their period before significant price cuts from roughly 14 years to 9 years. Rod notes that in oncology, where clinical trials take years, the shortened revenue period makes the expensive investment to move a drug from later-line to first-line therapy "uneconomical." "Most companies have already moved capital away from oncology, particularly small molecules." He uses antibiotics as an example, illustrating that when financial incentives are insufficient, development of entire drug classes (like novel antibiotics) stalls, creating a tragedy for society.
Rod Wong emphasizes that M&A is an intrinsic, not optional, part of the biotech ecosystem's success. Large pharma cannot fill pipeline gaps caused by patent expirations through internal R&D alone, while small companies need the distribution networks of large ones. This structure makes M&A a "very, very consistent" feature. He warns that policies attempting to block large companies from acquiring small biotechs would lead to slower drug launches, inefficient sales ("a thousand sales reps calling on the same doctor"), and hinder investors from recycling capital to fund more innovation. Currently, large companies face a wave of patent expirations, signaling the start of a new M&A cycle.
Rod Wong believes GLP-1 drugs (like Ozempic) will have a transformative impact, but market fears about their short-term disruption are overblown. He notes that a 20%-30% risk reduction in cardiovascular disease from GLP-1s will be "the single biggest factor impacting U.S. life expectancy for a very long time." However, with insurance reimbursement still not widespread, it could take a decade for penetration to rise from current single digits to the roughly two-thirds seen in mature categories (like blood pressure drugs), until the first drug's patent expires. Therefore, he believes that over the next 1-5 years, macroeconomic factors (like a recession) will have a much greater impact on related industries (e.g., Walmart) than GLP-1s.
| Position | Guest Stance | Key Data |
|---|---|---|
| Avexis | Successful investment case | Valued at ~$500M at time of investment; acquired by Novartis for ~$9B about 2 years later |
| Novo Nordisk | Industry winner | Stock price up ~7x over the past decade |
| Eli Lilly | Industry winner | Stock price up ~10x over the past decade |
| Merck | One of the industry winners | Stock price up ~2-3x over the past decade |
| AbbVie | One of the industry winners | Stock price up ~2-3x over the past decade |
| Pfizer, Bristol-Myers, Novartis, Roche, Sanofi | Underperformers | Stock prices roughly flat over the past decade |
| Valeant | Short target | Described as an "anti-biopharma" business model, now defunct |
1. Rod Wong: The product lifecycle of healthcare products is the key to understanding the entire industry. Rationale: A decade-plus of no revenue, capital intensity, followed by a rapid revenue cliff, creates a polarized industry structure (many micro-cap biotechs vs. a few large pharmas) and makes the U.S. the only capital market capable of deeply supporting the industry.
2. Rod Wong: New modalities like gene therapy are ushering in a "Golden Age of Drug Discovery." Rationale: Last year's record 61 U.S. drug approvals, with nearly 1/4 from new modalities; predicts 80-100 annual approvals in 5-10 years, with new modalities potentially accounting for half.
3. Rod Wong: The Inflation Reduction Act (IRA) is distorting investment decisions and suppressing innovation in oncology small molecules. Rationale: The act shortens the revenue period for small molecules from ~14 years to 9 years, making expensive clinical trials to advance drugs to first-line therapy uneconomical, leading to capital flight from the area.
4. Rod Wong: M&A is an intrinsic part of the biotech ecosystem's success and should not be hindered by policy. Rationale: Large companies need external innovation to fill pipelines; small companies need distribution channels. Blocking M&A would slow drug launches, create inefficiencies, and hinder capital recycling.
5. Rod Wong: The impact of GLP-1 drugs is long-term and transformative, but market fears about their short-term disruption are overblown. Rationale: Penetration will take about a decade to rise from single digits to mature levels; over the next 1-5 years, macroeconomic factors will have a much greater impact on related industries than GLP-1s.
6. Rod Wong: Identifying "predictive indicators of success" is the core competency in biotech investing. Rationale: Most drug development has a very high failure rate; the key is distinguishing which experimental results "translate nine times out of ten" from those that "translate one percent of the time," requiring deep pattern recognition and institutional knowledge.
7. Stephanie Sirota: To navigate the innovation explosion, investment firms must evolve into a "modern assembly line" of deeply specialized experts. Rationale: RTW grew from a small early team to ~75 people, including experts across therapeutic areas and functions. This team-based, deep specialization is a major challenge within the industry.
8. Rod Wong: The U.S. dominance in global biotech stems from the depth of its capital markets, not a monopoly on innovation sources. Rationale: Exciting innovation exists in Europe and China, but differences in capital markets mean these innovations often ultimately need to enter the U.S. market to achieve maximum value.